Save 20% on PRs and Gain Exclusive Benefits with NNW Prime! Click to View Details
WednesdayFeb 22, 2017 1:27 pm

NetworkNewsBreaks – Internap Corp. (NASDAQ: INAP) Shares Surge on $43M Private Placement, Revenue Guidance

Internap (NASDAQ: INAP) traded 26% higher mid-day after the company announced the private placement of approximately 23.8 million shares of its common stock at a price of $1.81 per share, for total gross proceeds of approximately $43 million. The funding in the private placement is provided by a group of investors that include affiliates of or funds managed by GAMCO Investors, Inc. and accounts advised by Avenir Corporation. The company intends to use the net proceeds of the offering to reduce debt. The settlement date for the transaction is February 27, 2017. Additionally, INAP reaffirmed guidance for 2016, including revenue…

Continue Reading

WednesdayFeb 22, 2017 1:23 pm

NetworkNewsBreaks – Zogenix, Inc. (NASDAQ: ZGNX) Has ‘Buy’ Rating Reiterated by Aegis Capital; Reaches Key Milestone in ZX008 Dravet Syndrome Phase 3 Program

Zogenix (NASDAQ: ZGNX) has been reiterated at a 'Buy' rating and $28 price target by Aegis Capital Corp. The company recently announced the initiation of the clinical efficacy portion of Study 1504 for ZX008 in patients with Dravet syndrome, a key milestone in the company’s phase 3 program. The two-cohort study will assess the pharmacokinetic and safety profile of single doses of ZX008, clobazam and valproate when added to stiripentol, followed by an evaluation of the efficacy, safety and tolerability of ZX008 as adjunctive antiepileptic therapy to a drug regimen that includes stiripentol, clobazam and valproate in a randomized, double-blind,…

Continue Reading

WednesdayFeb 22, 2017 1:20 pm

NetworkNewsBreaks – Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) Has ‘Buy’ Rating Reiterated by Aegis Capital

Noting Vanda Pharmaceuticals’ (NASDAQ: VNDA) recent financials and 2017 guidance, Aegis Capital Corp. has reiterated its 'Buy' rating and $24 price target on the company’s stock. Vanda reported net product sales for its melatonin receptor agonist, HETLIOZ®, at $71.7 million for full-year 2016, an increase of 62% compared to $44.3 million for the full year 2015. Fanapt®, the company’s atypical antipsychotic, brought in $74.3 million for the full year 2016, a 13% increase compared to $65.6 million in 2015. For the fourth quarter of 2016, Vanda reported non-GAAP net income of $3.6 million, compared to a non-GAAP net loss of…

Continue Reading

WednesdayFeb 22, 2017 11:17 am

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on February 22, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: TECR 43.59% – News: Chairman, CEO releases letter to shareholders SNGX 29.55% – News: Receives European patent for proprietary formulation of synthetic hypericin LNTH 22.99% – News: Moving on momentum from recent deal with GE Healthcare BIVI 20.00% – News: Submits response to FDA for BIV201 IND CDIF 15.68% – News:  Uplists to OTCQB venture market ZENO 15.00% – News: Initiates MIDS Medical Limited priority testing ESDI 13.55% – News: Endorses Craft Beverage Modernization…

Continue Reading

WednesdayFeb 22, 2017 10:54 am

NetworkNewsBreaks –, Inc. (CIIX) Presenting at SeeThruEquity Conference Later Today

Market analysis company, Inc. (OTCQB: CIIX) this morning announced that its management team will be presenting at the SeeThruEquity Conference in South Beach, Miami, later today. The presentation is scheduled to begin at 1:30 pm on February 22, 2017. Copies of presentation materials are currently available at In addition to this afternoon’s presentation, the company will also be holding meetings with potential investors on February 23-24 alongside the team from WallStreet Research™. A corporate profile covering CIIX created by WallStreet Research is available for download at To view the full press release, visit About Founded…

Continue Reading

WednesdayFeb 22, 2017 10:44 am

NetworkNewsBreaks – Stealth Technologies, Inc. (STTH) Attends Leading Real Estate, Home Staging Conference as Part of Strategic Growth Initiative

Security and personal protection company Stealth Technologies, Inc. (OTCQB: STTH) this morning offered an update on its attendance at the International Association of Home Staging Professionals (IAHSP) and Real Estate Conference Expo in Fort Lauderdale, Florida. The company recently attended the conference as part of its ongoing efforts to expand its product footprint across various industries and distributors, providing an opportunity for Stealth Technologies to showcase its innovative products while networking with key industry professionals. “We believe the conference was a success as it introduced our innovative products to various potential distributors and formed strategic relationships with industry leaders,” Brian…

Continue Reading

TuesdayFeb 21, 2017 11:50 am

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on February 21, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: PTLF 80.72% – News: Retains national PR firm to help bring cancer treatment to market PRTX 27.14% – News: Provides update on PRTX-100 studies in U.S. and EU PAYM 13.51% – News: Completes acquisition of Rockstar Acquisitions, LLC AEHR 10.90% – News: Receives $4M order for FOX-XP Test and Burn-in System PME 9.59% – News: Restates Q1 2017 EPS guidance of between $0.08 and $0.10 AETI 8.23% – News: Receives $6M of project awards…

Continue Reading

TuesdayFeb 21, 2017 11:50 am

NetworkNewsBreaks – Rentech, Inc. (NASDAQ: RTK) Plummets 45% on Halted Production at Wawa Facility

Shares of Rentech (NASDAQ: RTK) are down 46% following the company’s announcement that its board has decided to idle the Wawa facility due to equipment and operational issues that would require additional unbudgeted capital investment, as well as continued uncertainty around profitability on pellets produced at the facility. The company said it expects to complete a safe and orderly idling of the facility in approximately two weeks. After the plant is idled, a small number of workers will maintain the plant so that it can resume operations with minimal resources if there is interest from a third party to invest…

Continue Reading

TuesdayFeb 21, 2017 11:48 am

NetworkNewsBreaks – Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) Initiates Collaborative Research Program with Viatar for Early Pancreatic Cancer Detection

Interpace Diagnostics (NASDAQ: IDXG) is trading higher on news of its collaborative research program with Viatar CTC Solutions Inc. The partnership will combine Viatar's circulating tumor cell collection technology with Interpace's commercialized PancraGEN™ assay used to help assess unknown pancreatic cancer biopsies in patients with pancreatic cysts. Studies are being designed to identify patients most likely to develop pancreatic cancer in the near future as well as to detect pancreatic cancer at its earliest stage of development. These studies may lead to the enactment of early diagnostic testing and assessment for patients with pancreatic diseases, as well as for those…

Continue Reading

TuesdayFeb 21, 2017 10:06 am

NetworkNewsBreaks – EyeGate (NASDAQ: EYEG) Inks Licensing Deal with Valeant Pharmaceuticals (NYSE: VRX); Shares Higher

EyeGate Pharmaceuticals (NASDAQ: EYEG) is trading 39% higher this morning on news of its exclusive, worldwide licensing agreement with Valeant Pharmaceuticals (NYSE: VRX). Shares of Valeant are up 4%. The company has allowed a subsidiary of Valeant commercial and manufacturing rights to the EyeGate® II Delivery System and EGP-437 combination product candidate for the treatment of post-operative pain and inflammation in ocular surgery patients. Per the agreement, EyeGate received an upfront cash payment and will receive royalties on Valeant's net sales of the product. Additionally, the company may also receive development-based and sale-based milestone payments. This partnership follows a 2015…

Continue Reading

Contact us: 212.418.1217